Cybin (NEO: CYBN) (NYSE American: CYBN),a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its two lead clinical development programs: CYB003, a proprietary deuterated psilocybin analog for the potential treatment of major depressive disorder (“MDD”), and CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule being developed for the potential treatment of generalized anxiety disorder (“GAD”). According to the announcement, interim data from the CYB003 phase 1/2a study exhibited rapid and short-acting effects; strong psychedelic effects at low doses; and a positive safety and tolerability profile. The company anticipates having top-line efficacy data by late Q3 2023. In addition, initial findings from CYBN’s phase 1 CYB004-E study suggest that IV DMT is tolerated well, and the study design is being expanded to accelerate first-in-human dosing of CYB004. “It is incredibly gratifying that our findings from the interim readout of the CYB003 Phase 1/2a clinical trial align with the results observed in preclinical studies,” said Cybin CEO Doug Drysdale in the press release. “Robust psychedelic effects were observed at low doses, absorption was rapid with low variability, and effects were short lasting – all desired outcomes. These findings give us confidence in the potential efficacy of the underlying active agent, which may ultimately reduce symptoms of depression after just one or two doses. This would be a remarkable improvement over chronic treatments that are available today. . . . Our CYB004 program has made significant progress marked by confirmatory results from part A of the phase 1 CYB004-E trial and the acceleration of first-in-human dosing of CYB004. Recent protocol amendments will allow us to further evaluate CYB004 and demonstrate the advantages of deuteration on PK and PD parameters. We see the potential for short duration treatments, which could truly transform the treatment paradigm and outcomes for patients.”
To view the full press release, visit https://ibn.fm/6YDUv
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists and on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.